TARGETS TO THERAPIES: A NEW TARGET DE-RISKING INITIATIVE AT MJFF

Prioritizing and selecting emerging therapeutic targets for investment and development is a challenge across all therapeutic areas. To address this in Parkinson's disease (PD), the MJFF has established an industry- and investor-led initiative, called Targets to Therapies (T2T). It will aim to leverage the collective expertise of the PD research community to prioritize and de-risk promising therapeutic targets. In the first phase of this initiative, a community-driven survey nominated 280 promising therapeutic targets. Over the past year, a consortium of PD scientists, drug hunters, and investors conducted staged diligence to prioritize these targets, narrowing the list to ~20 promising candidates. The next phase will focus on validation strategies, building tools and resources to further de-risk these targets and position them for investment by industry and venture-backed communities.